The Chinese government has been deepening its reform over the past year in order to foster evolving regulatory framework. Deeper reforms coupled with a chilled market means life science companies should prioritize their assets and re-position their business strategies in order to survive and grow stronger.
IP specialists from FenXun Partners, which operates a joint legal platform with Baker McKenzie in China, highlight some key developments in China's IP legislation and rights protection rules in 2022. The authors also discuss new challenges and notable cases that illustrate the evolving IP landscape in China, and share their insights into the likely IP development trends in 2023.
Charles Wu and Zaiguang Lu of Han Kun Law Offices review the significant legislative developments of 2022 affecting China's private equity and venture capital industry, and offer insights into the key trends, challenges and opportunities in the sector
Nathan Bush, Nicholas Klein, Catherine Pawluch, and Alexandra Kamerling of DLA Piper survey the risks under the Foreign Direct Investment regimes of key jurisdictions, starting with the U.S., Canada, and the U.K. in this two-part series
After a busy year on the capital markets, Haiping Li and Paloma Wang of Skadden Arps Slate Meagher & Flom LLP take a look at 2022's developments and what the next 12 months may hold.
Jianwei Jerry Fang, Runyang Liu and Dianmeng Zhu of Zhong Lun Law Firm discuss the year's major legislative and judicial developments in civil and commercial dispute resolution in China.
Guanglei Zhang and Jinhui Zhang of Jingtian & Gongcheng examine the first decision of a Chinese court in which a secret pre-IPO agreement containing a valuation adjustment mechanism based on stock market price was declared invalid.
Geoffrey Chan, Sophie Xue, and Nicholas Poon of Skadden, Arps, Slate, Meagher & Flom examine how the Hong Kong Limited Partnership Fund, which serves as a cost and tax efficient vehicle for private equity transactions, could become a popular alternative to traditional offshore fund structures for PE investments and fundraising in Greater China
Daisy Duan and Sara Shi of King & Wood Mallesons review newly introduced regulations supporting pre-tax deductions for enterprise innovation in science and technology in China including recommended action to take advantage of these new tax preferential policies.
Christina Lee, Wang Hang, Dr. Matthias Courvoisier and Daisy Chen of Baker McKenzie and Stella Hu of FenXun Partners highlight the requirements, framework and benefits for listing global depository receipts (GDRs) on the SIX Swiss Exchange and discuss how it differs from the London Connect.
